Cystic Fibrosis drugs to cost €400 million over ten years

The HSE and the drug’s maker Vertex have reached a deal in principle on providing the drugs Orkambi and Kalydeco to CF patients

16th April, 2017

The deal to provide life-changing drugs to cystic fibrosis sufferers will cost the state close to €400 million over ten years.

The HSE and the drug’s maker Vertex have reached a deal in principle on providing the drugs Orkambi and Kalydeco to CF patients, but the final terms and conditions are still being worked out.

The final cost will be approved by ministers at a cabinet meeting before the end of the month,...

Subscribe from just €1 for the first month!

Currency

What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

Updated costs on new children’s hospital cannot be released, says Watt

Children from poorer families at a disadvantage in education and health, research shows

Tony O’Brien: Draft contract adds to bad blood between Department of Health and consultants

Health Tony O'Brien 6 days ago

Multi-annual health budget mooted to tackle waiting lists

Health Daniel Murray 1 week ago